SLNO News and Press, Soleno Therapeutics Inc.

REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking in...

2024-05-14 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-10 11:19:15 ET Baird has initiated Solerno Therapeutics ( NASDAQ: SLNO ) with a buy rating saying that they view U.S. approval of the company company's lead asset, an extended-release formulation of diazoxide choline (DCCR) for a condition associated with Prader-Willi synd...

2024-05-09 19:00:05 ET Brian Skorney from Robert W. Baird issued a price target of $72.00 for SLNO on 2024-05-09 16:09:00. The adjusted price target was set to $72.00. At the time of the announcement, SLNO was trading at $47.64. SLNO currently trades -13.14% versus its 5...

2024-05-09 17:51:15 ET More on Soleno Therapeutics Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch Soleno Therapeutics announces pricing of $138M public offering Soleno Therapeutics announces proposed common stock offering Seeking A...

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first qu...

2024-05-04 09:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-03 02:42:22 ET More on Soleno Therapeutics Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch Soleno Therapeutics announces proposed common stock offering Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha...

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing o...

2024-05-02 16:07:53 ET More on Soleno Therapeutics Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings...